Seattle Genetics to produce Lymphoma drug FDA (Reuters)
LOS ANGELES (Reuters) – a key trial Seattle Genetics tests with the patients antibodies targeting cancer n Hodgkin Lymphoma, it was found that more than a third of them achieved the complete remission of their cancer. The company also said it expects to produce drugs now, following the US regulatory authorities brentuximab vedotin (2) years from the date of the first quarter of patients either n Hodgkin Lymphoma or anaplastic large cell Lymphoma (ALCL) that have ceased responding to other therapies. The company had previously said it would take place in the first half of 2011, the consignment. "Our goal should be submitted in the first quarter of the year, and can be placed on the market of an accelerated review in 2011," Seattle Genetics CEO Siegall told Reuters the telephone Clay in the interview. The experiment to compare with another drug brentuximab vedotin, but similar patients full cancellation of the course is typically a single character, he said. The company is dev...